Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial
Journal Reference: Am J Gastroenterol 2024;119:1365–72 doi: 10.14309/ajg.0000000000002635
A combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy in patients with acute severe ulcerative colitis (ASUC). Singh et al. investigated whether addition of tofacitinib to corticosteroids was superior to corticosteroids alone in patients hospitalised with ASUC.
The improved response in patients receiving tofacitinib was sustained beyond 7 days; patients receiving tofacitinib displayed lower rates of both medical and surgical rescue therapy and a lower cumulative probability of need for rescue therapy at Day 90. Most of the treatment-related adverse effects were mild.
Keywords:
